- A151216 : Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
- SWOG S1400: Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
- E4512 : A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
- A081105 : Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
For more information, contact Cheryl Patz, RN, OCN, CCRC, at 360-788-8238.
3301 Squalicum PkwyBellingham, WA 98225